The Motley Fool
14 Nov 2026, 13:15 UTC · 2d ago
Bristol Myers Squibb's Growth Portfolio Now Brings In $7.7 Billion a Quarter. Here's Why That Changes the Stock's Story.
Impact · against what's priced in
The news regarding Bristol Myers Squibb's growth portfolio is positive but likely already reflected in the current valuation. While the $7.7 billion quarterly revenue from new drugs offsets patent cliffs, the market has already discounted this risk via a significant yield premium.
- BMY+0.10
No priced-in read yet





